Dichloroacetate (DCA) for Brain Cancer (Glioblastoma): Evidence Level Assessment

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Dichloroacetate (DCA) for Brain Cancer (Glioblastoma): Evidence Level Assessment

Understanding the evidence level for any compound is essential for making informed decisions. This page provides a structured evidence assessment for Dichloroacetate (DCA) in the context of Brain Cancer (Glioblastoma), following evidence-based medicine standards. This is a research summary — not medical advice.

Evidence Hierarchy Overview

Evidence in medicine is evaluated on a hierarchy from strongest to weakest:

  1. Level 1: Systematic reviews and meta-analyses of RCTs
  2. Level 2: Randomized controlled trials (RCTs)
  3. Level 3: Non-randomized controlled trials
  4. Level 4: Case-control and cohort studies
  5. Level 5: Case reports and expert opinion
  6. Preclinical: Animal and cell culture studies (not sufficient for clinical decisions)

Current Evidence Classification: Dichloroacetate (DCA) + Brain Cancer

Evidence level: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity

This evidence level reflects direct research on Dichloroacetate (DCA) in Brain Cancer contexts.

Mechanistic Evidence

Mechanistic plausibility does not equal clinical efficacy, but it helps contextualize why researchers investigate compounds. Dichloroacetate (DCA) operates via: Inhibits PDK; shifts glucose metabolism from glycolysis to OXPHOS; reactivates mitochondria in cancer cells; pro-apoptotic

This mechanism has documented relevance to Brain Cancer biology.

What This Evidence Level Means for Patients

An evidence level of "Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity" means:

  • Treatment decisions should not be based solely on this evidence
  • Enrollment in clinical trials (if available) may be the highest-evidence option
  • Compassionate use or off-label consideration requires careful risk/benefit analysis with your neuro-oncologist
  • The absence of strong evidence does not mean the compound doesn't work — it means we don't yet know

How Evidence Levels Evolve

The evidence for Dichloroacetate (DCA) in Brain Cancer may improve over time as more clinical trials are completed. Monitor ClinicalTrials.gov for emerging studies. Evidence levels are not permanent — they reflect the current state of published research.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What grade of evidence exists for Dichloroacetate (DCA) in Brain Cancer?

The current evidence classification is: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity. This is based on the available published literature as of 2026. Evidence grades can change as new clinical trials are completed and published.

Is the evidence strong enough to consider Dichloroacetate (DCA) for Brain Cancer?

Whether the current evidence level (Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity) is sufficient to consider Dichloroacetate (DCA) for your specific Brain Cancer case is a clinical decision that requires your neuro-oncologist's assessment of your individual circumstances, risk tolerance, and available alternatives.

Are there clinical trials that could improve the evidence for Dichloroacetate (DCA) in Brain Cancer?

To find active trials: search ClinicalTrials.gov for 'Dichloroacetate (DCA)' as intervention. Trial participation is how evidence levels improve over time. Ask your neuro-oncologist whether trial enrollment might be appropriate for your situation.